Core Viewpoint - InterCure Ltd. is acquiring Botanico Ltd. (known as ISHI) to enhance its global cannabis portfolio and gain access to premium American cultivation technology and brand partnerships, coinciding with potential regulatory changes in the cannabis industry [1][6]. Group 1: Acquisition Details - The acquisition will provide InterCure with ISHI's advanced AI-driven cultivation technologies, automated production systems, and exclusive brand alliances with leading U.S. operators [2]. - The deal is structured in two phases: InterCure will initially purchase 50% of ISHI's equity for 2.47 million ordinary shares, with the remaining 50% to be acquired upon ISHI achieving sustained profitability for three months or within two years, in exchange for an additional 2.46 million shares [4]. - The total deal represents approximately 10% of InterCure's fully diluted outstanding stock, with closing expected in the first quarter of 2026, pending regulatory approvals in Israel [4]. Group 2: Strategic Implications - The acquisition allows InterCure to immediately access award-winning American cannabis genetics and operational expertise through partnerships, including one with The Flowery, a prominent medical cannabis firm in Florida [3]. - ISHI's co-founders will join InterCure's leadership team, and all employee stock options at ISHI will convert to InterCure options under existing vesting terms, facilitating integration [5]. - This strategic move is viewed as a significant milestone by InterCure's CEO, positioning the company to leverage regulatory momentum and exclusive access to U.S. brands [6].